Nanoparticle News and Research

RSS

In nanotechnology, a particle is defined as a small object that behaves as a whole unit in terms of its transport and properties. It is further classified according to size: in terms of diameter, fine particles cover a range between 100 and 2500 nanometers, while ultrafine particles, on the other hand, are sized between 1 and 100 nanometers.

NanoSmart's ANA-conjugated liposomal doxorubicin receives FDA Orphan Drug Designation

NanoSmart Pharmaceuticals, Inc., a private pharmaceutical company developing nanoparticle drug delivery platforms, has received Orphan Drug Designation from the Food and Drug Administration for one of its lead candidates, antinuclear antibody (ANA) conjugated liposomal doxorubicin.

11 Feb 2015

Chili peppers show promise as diet-based supplement

Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.

9 Feb 2015

Johns Hopkins researchers successfully deliver new nanoparticle gene therapy to treat glioma in rats

Despite improvements in the past few decades with surgery, chemotherapy and radiation therapy, a predictably curative treatment for glioma does not yet exist. New insights into specific gene mutations that arise in this often deadly form of brain cancer have pointed to the potential of gene therapy, but it's very difficult to effectively deliver toxic or missing genes to cancer cells in the brain.

5 Feb 2015

Study demonstrates therapeutic potential of new class of synthetic oligonucleotides for DMD treatment

Research efforts associating scientists from the CNRS, UVSQ and INSERM within the Laboratoire END-ICAP, working in collaboration with a team from the University of Bern, has demonstrated the therapeutic potential of a new class of synthetic oligonucleotides in the treatment of Duchenne muscular dystrophy (DMD) using RNA "surgery".

4 Feb 2015

Cell-penetrating nanoparticles can efficiently transport oligonucleotide drugs into cells

Therapeutic oligonucleotide analogs represent a new and promising family of drugs that act on nucleic acid targets such as RNA or DNA; however, their effectiveness has been limited due to difficulty crossing the cell membrane.

31 Jan 2015

Case Western researchers awarded NSF grant to develop new method to reduce risk of Ebola virus

Health care workers must diagnose and isolate Ebola victims at an early stage to have a chance to save them and prevent the virus from spreading. But the most sensitive and quickest diagnostic test produces a small percentage of false negative results that undermine efforts to control the deadly agent.

27 Jan 2015

UB researchers design nanoparticle that may open door for new 'hypermodal' imaging systems

Using two biocompatible parts, University at Buffalo researchers and their colleagues have designed a nanoparticle that can be detected by six medical imaging techniques.

21 Jan 2015

Celator Pharmaceuticals' CPX-351 receives FDA Fast Track designation for secondary AML treatment

Celator Pharmaceuticals, Inc., a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that the U.S. Food and Drug Administration granted Fast Track designation for CPX-351 (cytarabine:daunorubicin) for the treatment of elderly patients with secondary Acute Myeloid Leukemia (AML).

20 Jan 2015

Precision NanoSystems, Arcturus Therapeutics partner to develop RNA medicines

Precision NanoSystems, a leader in the development and application of microfluidics for the manufacture of nanomedicines; and, Arcturus Therapeutics, a leading small interfering RNA (siRNA) and messenger RNA (mRNA) drug discovery and development company, today announced a partnership for the manufacture of RNA medicines.

From Precision NanoSystems Inc. 11 Jan 2015

Exposure to nanoparticles can play major role in development of cardiovascular diseases

Nanoparticles, extremely tiny particles measured in billionths of a meter, are increasingly everywhere, and especially in biomedical products. Their toxicity has been researched in general terms, but now a team of Israeli scientists has for the first time found that exposure nanoparticles (NPs) of silicon dioxide (SiO2) can play a major role in the development of cardiovascular diseases when the NP cross tissue and cellular barriers and also find their way into the circulatory system.

8 Jan 2015

EnGeneIC closes oversubscribed Series B financing

EnGeneIC, Ltd., an emerging biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutics, announced it has completed an oversubscribed $10 million Series B financing.

6 Jan 2015

Sirnaomics submits STP705 IND Application to CFDA for skin scar treatment

Sirnaomics, Inc. and its affiliate Suzhou Sirnaomics Pharmaceutics, Co. Ltd., together with its partner Guangzhou Xiangxue Pharmaceutical, Co. Ltd., (SZSE: 300147), have formally submitted an Investigational New Drug (IND) Application to the China Food and Drug Administration for STP705, an anti-fibrosis RNA interference (RNAi) therapeutic for prevention and treatment of human skin hypertrophic scars.

5 Jan 2015

MIT engineers create new computer model to design complex 3-D DNA shapes

MIT biological engineers have created a new computer model that allows them to design the most complex three-dimensional DNA shapes ever produced, including rings, bowls, and geometric structures such as icosahedrons that resemble viral particles.

3 Dec 2014

Ceres to develop new method for detecting the presence of Ebola virus in saliva

Ceres Nanosciences Inc. today announced the commencement of a development program, funded by the Gates Foundation, to use Ceres' Nanotrap particle technology to develop a new method of detecting the presence of the Ebola virus in saliva.

3 Dec 2014

Immune Pharmaceuticals closes underwriter's exercise of partial over-allotment option of 459,697 units

Immune Pharmaceuticals Inc., a clinical stage biopharmaceutical company that engages in the development and commercialization of targeted therapeutics for the treatment of inflammatory diseases and cancer, today completed the underwriter's exercise of partial over-allotment option of 459,697 units, at a price of $2.50 per unit, for gross proceeds of approximately $1.06 million, bringing the aggregate gross proceeds of the Company's previously announced underwritten public offering to $9.685 million.

27 Nov 2014

Therapeutic nanoparticle safe, effective against H. pylori infection, shows study

The bacterium Helicobacter pylori is strongly associated with gastric ulcers and cancer. To combat the infection, researchers at University of California, San Diego School of Medicine and Jacobs School of Engineering developed LipoLLA, a therapeutic nanoparticle that contains linolenic acid, a component in vegetable oils.

27 Nov 2014

Nanoparticle News and Research

Further Reading

NanoSmart's ANA-conjugated liposomal doxorubicin receives FDA Orphan Drug Designation

Chili peppers show promise as diet-based supplement

Johns Hopkins researchers successfully deliver new nanoparticle gene therapy to treat glioma in rats

Study demonstrates therapeutic potential of new class of synthetic oligonucleotides for DMD treatment

Cell-penetrating nanoparticles can efficiently transport oligonucleotide drugs into cells

Case Western researchers awarded NSF grant to develop new method to reduce risk of Ebola virus

UB researchers design nanoparticle that may open door for new 'hypermodal' imaging systems

Celator Pharmaceuticals' CPX-351 receives FDA Fast Track designation for secondary AML treatment

Precision NanoSystems, Arcturus Therapeutics partner to develop RNA medicines

Exposure to nanoparticles can play major role in development of cardiovascular diseases

EnGeneIC closes oversubscribed Series B financing

Sirnaomics submits STP705 IND Application to CFDA for skin scar treatment

MIT engineers create new computer model to design complex 3-D DNA shapes

Ceres to develop new method for detecting the presence of Ebola virus in saliva

Immune Pharmaceuticals closes underwriter's exercise of partial over-allotment option of 459,697 units

Therapeutic nanoparticle safe, effective against H. pylori infection, shows study

Next-generation biomarker detects tumour cells, delivers anti-cancer drugs

Researchers discover new method to deliver drugs into aggressive tumors

WSU researchers working on new system to reduce negative effects of cancer drugs

CytoFLEX flow cytometer from Beckman Coulter Life Sciences delivers full analysis capabilities

How to solve the hidden bottleneck in lipid nanoparticle development eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo